Transplatin: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Transplatin}} | ||
}} | |||
'''Transplatin''' | == Overview == | ||
[[File:TransPtCl2A2.svg|thumb|right|Structure of Transplatin]] | |||
'''Transplatin''' is a [[platinum-based chemotherapy]] drug that is an isomer of the more widely known [[cisplatin]]. Unlike cisplatin, which is used in the treatment of various types of [[cancer]], transplatin is not effective as an anticancer agent. This difference in activity is primarily due to the distinct geometric configuration of the two compounds. | |||
==Structure | == Chemical Structure == | ||
Transplatin | Transplatin, or trans-diamminedichloroplatinum(II), has a [[square planar]] geometry with two [[ammonia]] molecules and two [[chloride]] ions arranged in a trans configuration around a central platinum atom. This configuration is in contrast to the cis configuration found in cisplatin, where the ligands are adjacent to each other. | ||
The | == Mechanism of Action == | ||
The lack of anticancer activity in transplatin is attributed to its inability to form the same type of [[DNA cross-links]] as cisplatin. In cisplatin, the cis configuration allows the formation of intrastrand cross-links between adjacent [[guanine]] bases on [[DNA]], which is crucial for its cytotoxic effects. Transplatin, however, forms interstrand cross-links that are less effective at disrupting DNA function. | |||
== | == Clinical Use == | ||
Transplatin | Transplatin is not used in clinical settings for cancer treatment due to its poor efficacy. However, it has been studied for its potential use in combination with other drugs or as a scaffold for developing new platinum-based compounds with improved activity and reduced side effects. | ||
== | == Research and Development == | ||
Research into transplatin and its derivatives continues, as scientists seek to understand the structural and chemical properties that influence the activity of platinum-based drugs. Modifications to the transplatin structure, such as changing the ligands or altering the platinum coordination environment, are being explored to enhance its therapeutic potential. | |||
==Related | == Related Pages == | ||
* [[Cisplatin]] | * [[Cisplatin]] | ||
* [[ | * [[Platinum-based chemotherapy]] | ||
* [[DNA cross-linking]] | |||
* [[ | |||
[[Category:Chemotherapy]] | |||
[[Category:Platinum compounds]] | [[Category:Platinum compounds]] | ||
Latest revision as of 03:41, 13 February 2025
Overview[edit]
Transplatin is a platinum-based chemotherapy drug that is an isomer of the more widely known cisplatin. Unlike cisplatin, which is used in the treatment of various types of cancer, transplatin is not effective as an anticancer agent. This difference in activity is primarily due to the distinct geometric configuration of the two compounds.
Chemical Structure[edit]
Transplatin, or trans-diamminedichloroplatinum(II), has a square planar geometry with two ammonia molecules and two chloride ions arranged in a trans configuration around a central platinum atom. This configuration is in contrast to the cis configuration found in cisplatin, where the ligands are adjacent to each other.
Mechanism of Action[edit]
The lack of anticancer activity in transplatin is attributed to its inability to form the same type of DNA cross-links as cisplatin. In cisplatin, the cis configuration allows the formation of intrastrand cross-links between adjacent guanine bases on DNA, which is crucial for its cytotoxic effects. Transplatin, however, forms interstrand cross-links that are less effective at disrupting DNA function.
Clinical Use[edit]
Transplatin is not used in clinical settings for cancer treatment due to its poor efficacy. However, it has been studied for its potential use in combination with other drugs or as a scaffold for developing new platinum-based compounds with improved activity and reduced side effects.
Research and Development[edit]
Research into transplatin and its derivatives continues, as scientists seek to understand the structural and chemical properties that influence the activity of platinum-based drugs. Modifications to the transplatin structure, such as changing the ligands or altering the platinum coordination environment, are being explored to enhance its therapeutic potential.
